NEW YORK, June 5, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results